reports
Hanssem Co: 1 director
A director at Hanssem Co bought 4,800 shares at 42,532.000KRW and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
HANSSEM increases its risk exposure and slightly lowers to Neutral
HANSSEM (KR), a company active in the Furnishings industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date December 14, 2021, the closing price was KRW 92,300.00 and i...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Stay Defensive With Technology, Health Care, Staples Upside momentum continues to wane for global equities, a trend we mentioned in last week's Int'l Compass. In that report we highlighted early signs of lower highs forming in the major global indexes. Price action this week has indeed confirmed lower highs for now in the MSCI ACWI, ACWI ex-US, EAFE, and EM indexes. These lower highs increase the probability for breakdowns and a deeper pullback, but we do not want to get ahead of ourselves. Unt...
RECSI REC SILICON ASA
SWMA SWEDISH MATCH AB
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
2347 SYNNEX TECHNOLOGY INTERNATIONAL CORP.
HIK HIKMA PHARMACEUTICALS PLC
BIMBO.A GRUPO BIMBO SAB DE CV CLASS A
000858 WULIANGYE YIBIN CO. LTD. CLASS A
4755 RAKUTEN INC.
6702 FUJITSU LIMITED
4528 ONO PHARMACEUTICAL CO. LTD.
600809 SHANXI XINGHUACUN FEN WINE FACTORY CO. LTD. CLASS A
4568 DAIICHI SANKYO COMPANY LIMITED
095700 GENEXINE
300015 AIER EYE HOSPITAL GROUP CO. LTD. CLASS A
002507 CHONGQING FULING ZHACAI GROUP CO. LTD. CLASS A
KDIC KINGDEE INTERNATIONAL SOFTWARE GROUP CO. LTD.
600519 KWEICHOW MOUTAI CO. LTD. CLASS A
4552 JCR PHARMACEUTICALS CO. LTD.
600597 BRIGHT DAIRY & FOOD CO. LTD. A
600436 ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO. LTD. CLASS A
9989 SUNDRUG CO. LTD.
600872 JONJEE HI-TECH INDUSTRIAL AND COMMERCIAL HOLDING CO. LTD. CLASS A
097950 CJ CHEILJEDANG CORPORATION
002262 JIANGSU NHWA PHARMACEUTICAL (A)
300357 ZHEJIANG WOLWO BIO-PHARMACEUTICAL CO. LTD. CLASS A
603288 FOSHAN HAITIAN FLAVOURING & FOOD CO. LTD. CLASS A
00700 TENCENT HOLDINGS LTD.
009240 HANSSEM CO. LTD
LOGN LOGANSPORT FIN
PRX PROSUS N.V. CLASS N
1579 NIKKEI225 BULL 2X ETF
300725 PHARMABLOCK SCIENCES (NANJING) (A)
300783 THREE SQUIRRELS (A)
2448 SPACE GROUP HOLDINGS LTD.
ATM AFRITIN MINING
00512 CHINA GRAND PHARMACEUTICAL & HEALTHCARE HOLDINGS (P CHIP)
603156 HEBEI YANGYUAN ZHIHUI BEVERAGE CO. LTD. CLASS A
002946 NEW HOPE DAIRY (A)
603317 SICHUAN TEWAY FOOD GROUP (A)
- Jung-hwan Sung
Hanssem (009240.KS): Deconstruction
Sales on a parent basis slipped 5.5% YoY to KRW467.5bn and operating profit fell 56.3% YoY to KRW17.8bn in 1Q18. - Margins fell sharply as well, due to a decrease in B2C sales, higher cost ratio stemming from B2B sales growth, and escalating marketing costs amid efforts to boost sales. - We maintain Marketperform but reduce our target price from KRW170,000 to KRW155,000.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.